Hyeseon Cho,Kristina Kay Gonzales-Wartz,Deli Huang,Meng Yuan,Mary Peterson,Janie Liang,Nathan Beutler,Jonathan L. Torres,Yu Cong,Elena Postnikova,Sandhya Bangaru,Chloe Adrienna Talana,Wei Shi,Eun Sung Yang,Yi Zhang,Kwanyee Leung,Lingshu Wang,Linghang Peng,Jeff Skinner,Shanping Li,Nicholas C. Wu,Hejun Liu,Cherrelle Dacon,Thomas Moyer,Melanie Cohen,Ming Zhao,Frances Eun-Hyung Lee,Rona S. Weinberg,Iyadh Douagi,Robin Gross,Connie Schmaljohn,Amarendra Pegu,John R. Mascola,Michael Holbrook,David Nemazee,Thomas F. Rogers,Andrew B. Ward,Ian A. Wilson,Peter D. Crompton,Joshua Tan

Abstract:The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern threatens the efficacy of existing vaccines and therapeutic antibodies and underscores the need for additional antibody-based tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal antibodies targeting SARS-CoV-2 from plasmablasts and memory B cells collected from patients with coronavirus disease 2019. The three most potent antibodies targeted distinct regions of the receptor binding domain (RBD), and all three neutralized the SARS-CoV-2 Alpha and Beta variants. The crystal structure of the most potent antibody, CV503, revealed that it binds to the ridge region of SARS-CoV-2 RBD, competes with the angiotensin-converting enzyme 2 receptor, and has limited contact with key variant residues K417, E484, and N501. We designed bispecific antibodies by combining nonoverlapping specificities and identified five bispecific antibodies that inhibit SARS-CoV-2 infection at concentrations of less than 1 ng/ml. Through a distinct mode of action, three bispecific antibodies cross-linked adjacent spike proteins using dual N-terminal domain–RBD specificities. One bispecific antibody was greater than 100-fold more potent than a cocktail of its parent monoclonals in vitro and prevented clinical disease in a hamster model at a dose of 2.5 mg/kg. Two bispecific antibodies in our panel comparably neutralized the Alpha, Beta, Gamma, and Delta variants and wild-type virus. Furthermore, a bispecific antibody that neutralized the Beta variant protected hamsters against SARS-CoV-2 expressing the E484K mutation. Thus, bispecific antibodies represent a promising next-generation countermeasure against SARS-CoV-2 variants of concern.

hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants

Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection

A Non-Ace2 Competing Human Single-Domain Antibody Confers Broad Neutralization Against SARS-CoV-2 and Circulating Variants.

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

Etesevimab in Combination with JS026 Neutralizing SARS-CoV-2 and Its Variants

Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages

Structure-guided antibody cocktail for prevention and treatment of COVID-19

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Potently neutralizing and protective human antibodies against SARS-CoV-2

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Protective Efficacy of Novel Engineered Human ACE2-Fc Fusion Protein Against Pan-SARS-CoV-2 Infection In Vitro and in Vivo

Structure-based development of human antibody cocktails against SARS-CoV-2

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants